<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">ppan</journal-id><journal-title-group><journal-title xml:lang="en">Personalized Psychiatry and Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Personalized Psychiatry and Neurology</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2712-9179</issn><publisher><publisher-name>V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52667/2712-9179-2023-3-1-3-6</article-id><article-id custom-type="elpub" pub-id-type="custom">ppan-62</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>New Hope: Using Gene Therapy to Treat Rare Neurological Diseases</article-title><trans-title-group xml:lang="ru"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Rizvanov</surname><given-names>A. A</given-names></name></name-alternatives><bio xml:lang="en"><p>Albert A. Rizvanov</p><p>Kazan</p><p>Tel.: +7 (843) 293-43-07</p></bio><email xlink:type="simple">Albert.Rizvanov@kpfu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="en" id="aff-1"><institution>Kazan Federal University</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>17</day><month>05</month><year>2023</year></pub-date><volume>3</volume><issue>1</issue><fpage>3</fpage><lpage>6</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Rizvanov A.A., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Rizvanov A.A.</copyright-holder><copyright-holder xml:lang="en">Rizvanov A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jppn.ru/jour/article/view/62">https://www.jppn.ru/jour/article/view/62</self-uri><abstract><p>Gene therapy is a promising treatment approach for rare/orphan neurological diseases that have limited treatment options and no cure. This article provides a brief overview of different types of rare hereditary neurological diseases and discusses existing gene therapy drugs approved for their treatment. Despite challenges associated with the development and implementation of gene therapy, including cost, delivery, and long-term safety and efficacy, the potential benefits of gene therapy make it a compelling area of research for the treatment of rare hereditary neurological diseases.</p></abstract><kwd-group xml:lang="en"><kwd>gene therapy</kwd><kwd>hereditary neurological diseases</kwd><kwd>orphan diseases</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This paper has been supported by the Kazan Federal University Strategic Academic Leadership Program (PRIORITY-2030).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Flotte, T.R., Gessler, D.J. Gene Therapy for Rare Neurological Disorders. Clin Pharmacol Ther. 2022; 111(4): 743-757. DOI: 10.1002/cpt.2543.</mixed-citation><mixed-citation xml:lang="en">Flotte, T.R., Gessler, D.J. Gene Therapy for Rare Neurological Disorders. Clin Pharmacol Ther. 2022; 111(4): 743-757. DOI: 10.1002/cpt.2543.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ravi, B., Chan-Cortes, M.H., Sumner, C.J. Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy. Annu Rev Med. 2021; 72: 1-14. DOI: 10.1146/annurev-med-070119-115459.</mixed-citation><mixed-citation xml:lang="en">Ravi, B., Chan-Cortes, M.H., Sumner, C.J. Gene-Targeting Therapeutics for Neurological Disease: Lessons Learned from Spinal Muscular Atrophy. Annu Rev Med. 2021; 72: 1-14. DOI: 10.1146/annurev-med-070119-115459.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shaimardanova, A.A., Chulpanova, D.S., Solovyeva, V.V., Mullagulova, A.I., Kitaeva, K.V., Allegrucci, C., Rizvanov, A.A. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Front Med (Lausanne). 2020; 7: 576221. DOI: 10.3389/fmed.2020.576221.</mixed-citation><mixed-citation xml:lang="en">Shaimardanova, A.A., Chulpanova, D.S., Solovyeva, V.V., Mullagulova, A.I., Kitaeva, K.V., Allegrucci, C., Rizvanov, A.A. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Front Med (Lausanne). 2020; 7: 576221. DOI: 10.3389/fmed.2020.576221.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Shaimardanova, A.A., Solovyeva, V.V., Issa, S.S., Rizvanov, A.A. Gene Therapy of Sphingolipid Metabolic Disorders. International Journal of Molecular Sciences. 2023; 24(4). DOI: 10.3390/ijms24043627.</mixed-citation><mixed-citation xml:lang="en">Shaimardanova, A.A., Solovyeva, V.V., Issa, S.S., Rizvanov, A.A. Gene Therapy of Sphingolipid Metabolic Disorders. International Journal of Molecular Sciences. 2023; 24(4). DOI: 10.3390/ijms24043627.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Stoker, T.B., Mason, S.L., Greenland, J.C., Holden, S.T., Santini, H., Barker, R.A. Huntington's disease: diagnosis and management. Pract Neurol. 2022; 22(1): 32-41. DOI: 10.1136/practneurol-2021-003074.</mixed-citation><mixed-citation xml:lang="en">Stoker, T.B., Mason, S.L., Greenland, J.C., Holden, S.T., Santini, H., Barker, R.A. Huntington's disease: diagnosis and management. Pract Neurol. 2022; 22(1): 32-41. DOI: 10.1136/practneurol-2021-003074.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vazquez-Mojena, Y., Leon-Arcia, K., Gonzalez-Zaldivar, Y., Rodriguez-Labrada, R., Velazquez-Perez, L. Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives. Mov Disord. 2021; 36(12): 2731-2744. DOI: 10.1002/mds.28819.</mixed-citation><mixed-citation xml:lang="en">Vazquez-Mojena, Y., Leon-Arcia, K., Gonzalez-Zaldivar, Y., Rodriguez-Labrada, R., Velazquez-Perez, L. Gene Therapy for Polyglutamine Spinocerebellar Ataxias: Advances, Challenges, and Perspectives. Mov Disord. 2021; 36(12): 2731-2744. DOI: 10.1002/mds.28819.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Turk, B.R., Theda, C., Fatemi, A., Moser, A.B. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020; 80(1): 52-72. DOI: 10.1002/jdn.10003.</mixed-citation><mixed-citation xml:lang="en">Turk, B.R., Theda, C., Fatemi, A., Moser, A.B. X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020; 80(1): 52-72. DOI: 10.1002/jdn.10003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shaimardanova, A.A., Chulpanova, D.S., Solovyeva, V.V., Aimaletdinov, A.M., Rizvanov, A.A. Functionality of a bicistronic construction containing HEXA and HEXB genes encoding beta-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses. Neural Regen Res. 2022; 17(1): 122-129. DOI: 10.4103/1673-5374.314310.</mixed-citation><mixed-citation xml:lang="en">Shaimardanova, A.A., Chulpanova, D.S., Solovyeva, V.V., Aimaletdinov, A.M., Rizvanov, A.A. Functionality of a bicistronic construction containing HEXA and HEXB genes encoding beta-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses. Neural Regen Res. 2022; 17(1): 122-129. DOI: 10.4103/1673-5374.314310.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Davletshin, E., Sabirov, D., Rizvanov, A., Mukhamedshina, Y. Combined Approaches Leading to Synergistic Therapeutic Effects in Spinal Cord Injury: State of the Art. Front Biosci (Landmark Ed). 2022; 27(12): 334. DOI: 10.31083/j.fbl2712334.</mixed-citation><mixed-citation xml:lang="en">Davletshin, E., Sabirov, D., Rizvanov, A., Mukhamedshina, Y. Combined Approaches Leading to Synergistic Therapeutic Effects in Spinal Cord Injury: State of the Art. Front Biosci (Landmark Ed). 2022; 27(12): 334. DOI: 10.31083/j.fbl2712334.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ebrahim, N., James, V., Rizvanov, A.A., Mukhamedshina, Y. Genetic Modification of Mesenchymal Stem Cells for Neurological Disease Therapy: What Effects Does it Have on Phenotype/Cell Behavior, Determining Their Effectiveness? Mol Diagn Ther. 2020; 24(6): 683-702. DOI: 10.1007/s40291-020-00491-6.</mixed-citation><mixed-citation xml:lang="en">Ebrahim, N., James, V., Rizvanov, A.A., Mukhamedshina, Y. Genetic Modification of Mesenchymal Stem Cells for Neurological Disease Therapy: What Effects Does it Have on Phenotype/Cell Behavior, Determining Their Effectiveness? Mol Diagn Ther. 2020; 24(6): 683-702. DOI: 10.1007/s40291-020-00491-6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
